Unknown

Dataset Information

0

Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer.


ABSTRACT: This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from baseline) by MRI was 90.5% and 40.0% (6 of 15) of patients who received only niraparib (2-6 cycles) had pathological complete response; no new safety signals were identified. High niraparib intratumoral concentration was observed.

SUBMITTER: Spring LM 

PROVIDER: S-EPMC9402431 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications


This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from baseline) by MRI was 90.5% and 40.0% (6 of 15) of patients who received only niraparib (2-6 cycles) had pathological complete response; no new safety signals were identified. High niraparib intratumo  ...[more]

Similar Datasets

| S-EPMC10166159 | biostudies-literature
| S-EPMC5994186 | biostudies-literature
| S-EPMC9966507 | biostudies-literature
| S-EPMC7985189 | biostudies-literature
| S-EPMC10536506 | biostudies-literature
| S-EPMC8993712 | biostudies-literature
| S-EPMC7212882 | biostudies-literature
| S-EPMC10865976 | biostudies-literature
| S-EPMC10948524 | biostudies-literature
| S-EPMC9365365 | biostudies-literature